Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AirSculpt TechnologiesAIRS +11.37%73 EV-to-EBITDA is 428.62 as of Jul. 30, 2026, which is 1028% above its 10-year median of 37.99. GuruFocus rates AIRS with a GF Score™ of 73/100 and a GF Value™ of $3.88 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 509 Healthcare Providers & Services companies, AirSculpt Technologies ranks worse than 98.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AirSculpt Technologies's enterprise value is $396.5 Mil.
AirSculpt Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.9 Mil. Therefore, AirSculpt Technologies's EV-to-EBITDA for today is 428.62.
The historical rank and industry rank for AirSculpt Technologies's EV-to-EBITDA or its related term are showing as below:
AIRS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -472.63 Med: 37.99 Max: 463.48
Current: 428.62
During the past 7 years, the highest EV-to-EBITDA of AirSculpt Technologies was 463.48. The lowest was -472.63. And the median was 37.99.
AIRS's EV-to-EBITDA is ranked worse than 98.23% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.01
vs AIRS: 428.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AirSculpt Technologies's PE Ratio (TTM) for today is calculated as:
AirSculpt Technologies's share price for today is $4.85.
AirSculpt Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, AirSculpt Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AirSculpt Technologies EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AirSculpt Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AirSculpt Technologies's EV-to-EBITDA falls into.
AirSculpt Technologies's current Enterprise Value is $396.5 Mil.
AirSculpt Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AirSculpt Technologies (AIRS) has a EV-to-EBITDA of 428.62 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AirSculpt Technologies. This is 1028% above median its historical median of 37.99. According to the industry distribution chart, AirSculpt Technologies ranks #500 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 98.2%.
Is AirSculpt Technologies' EV-to-EBITDA too high?
AirSculpt Technologies' current EV-to-EBITDA of 428.62 is 1028% above median its 10-year median of 37.99. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.01. AirSculpt Technologies' value of 428.62 is 3793% above this industry median. Based on the distribution chart, AirSculpt Technologies ranks #500 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, AirSculpt Technologies has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AirSculpt Technologies' EV-to-EBITDA compare to AUNA and CYH?
According to the Healthcare Providers & Services industry distribution chart, AirSculpt Technologies ranks #500 out of 509 companies for EV-to-EBITDA. This places AirSculpt Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 11.01. AirSculpt Technologies' value of 428.62 is 3793% above this benchmark. While the company's 10-year median is 37.99 vs. the industry median of 11.01, AirSculpt Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.01, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AirSculpt Technologies's current EV-to-EBITDA of 428.62 is 3793% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AirSculpt Technologies. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AirSculpt Technologies's current EV-to-EBITDA is 428.62, which is 1028% above median its own 10-year median of 37.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AirSculpt Technologies stock overvalued right now?
Based on GuruFocus' analysis, AirSculpt Technologies (AIRS) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.88, compared to a current price of $4.85 — trading 25% above its estimated fair value. The current EV-to-EBITDA is 428.62, which is 1028% above median its 10-year median of 37.99 and 3793% above the Healthcare Providers & Services industry median of 11.01. AirSculpt Technologies' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AirSculpt Technologies (AIRS), the current EV-to-EBITDA is 428.62 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AirSculpt Technologies (AIRS) Overvalued in 2026?
Based on GuruFocus' analysis, AirSculpt Technologies stock appears to be overvalued.
The current stock price of $4.85 is trading 25% above its estimated GF Value™ of $3.88.
GuruFocus considers AirSculpt Technologies to be Modestly Overvalued.
Key valuation signals for AIRS:
EV-to-EBITDA: 428.62 (1028% above median its 10-year median of 37.99)
GF Value™: $3.88 vs. price of $4.85 (25% above fair value)
Industry Position: 3793% above the Healthcare Providers & Services median (#500 of 509)
No single metric tells the full story. See the AIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
73GF Score
Get the complete analysis for AIRS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRS has been successfully added to your 
